Published in J Neurovirol on October 01, 2010
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol (1989) 5.77
Temperature-sensitive mutants of herpes simplex virus type 1: isolation, complementation and partial characterization. Virology (1973) 5.10
Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A (1996) 4.16
p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature (1994) 3.95
Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A (1989) 3.26
Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J Virol (1990) 3.05
Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron (1997) 2.96
A brain-specific activator of cyclin-dependent kinase 5. Nature (1994) 2.71
The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev (1996) 2.59
Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. J Virol (1995) 2.26
Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron (2003) 2.19
The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature (1998) 2.01
p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci (2001) 1.87
Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol (1998) 1.80
Extraneuronal roles of cyclin-dependent kinase 5. Bioessays (2006) 1.65
De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog (2009) 1.56
Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo. J Virol (2000) 1.45
Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol (2002) 1.38
Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J Virol (1999) 1.38
Restricted expression of herpes simplex virus lytic genes during establishment of latent infection by thymidine kinase-negative mutant viruses. J Virol (1990) 1.35
Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity. Proc Natl Acad Sci U S A (2004) 1.27
Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J Virol (2000) 1.25
Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J Cell Sci (2007) 1.17
Point mutations in herpes simplex virus type 1 oriL, but not in oriS, reduce pathogenesis during acute infection of mice and impair reactivation from latency. J Virol (2006) 1.10
Posttranslational processing of infected cell proteins 0 and 4 of herpes simplex virus 1 is sequential and reflects the subcellular compartment in which the proteins localize. J Virol (2001) 1.09
The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0. J Virol (2002) 1.08
Cdk5 nuclear localization is p27-dependent in nerve cells: implications for cell cycle suppression and caspase-3 activation. J Biol Chem (2010) 1.06
The protein SET binds the neuronal Cdk5 activator p35nck5a and modulates Cdk5/p35nck5a activity. J Biol Chem (2001) 1.02
CDK5 regulates cell adhesion and migration in corneal epithelial cells. Mol Cancer Res (2002) 1.01
Re-evaluating natural resistance to herpes simplex virus type 1. J Virol (2004) 0.99
Role of the VP16-binding domain of vhs in viral growth, host shutoff activity, and pathogenesis. J Virol (2004) 0.96
Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4. J Virol (2002) 0.94
Cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activators. Prog Cell Cycle Res (1996) 0.92
Intracellular localization of cyclin-dependent kinase 5 (CDK5) in mouse neuron: CDK5 is located in both nucleus and cytoplasm. Brain Res (1996) 0.85
Herpesvirus infection of ICAM-1-deficient mice. Curr Eye Res (2004) 0.83
A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem (2003) 2.69
Copy number variation of multiple genes at Rhg1 mediates nematode resistance in soybean. Science (2012) 2.01
Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol (2012) 1.59
Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro (2010) 1.21
Ceramide displaces cholesterol from lipid rafts and decreases the association of the cholesterol binding protein caveolin-1. J Lipid Res (2005) 1.21
Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats. Diabetes (2010) 1.18
Genome sequence of herpes simplex virus 1 strain KOS. J Virol (2012) 1.12
Hyperglycemia alters the schwann cell mitochondrial proteome and decreases coupled respiration in the absence of superoxide production. J Proteome Res (2010) 1.08
Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach? Pharmacol Rev (2012) 0.99
Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy. Diabetes (2009) 0.98
Hyperglycemia and downregulation of caveolin-1 enhance neuregulin-induced demyelination. Glia (2008) 0.98
Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J Neurochem (2003) 0.98
Nutrient excess and altered mitochondrial proteome and function contribute to neurodegeneration in diabetes. Mitochondrion (2011) 0.96
Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res (2005) 0.96
C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons. J Proteome Res (2012) 0.96
HSV-1 ICP0: paving the way for viral replication. Future Virol (2011) 0.94
Role of nuclear factor Y in stress-induced activation of the herpes simplex virus type 1 ICP0 promoter. J Virol (2010) 0.89
Transient expression of herpes simplex virus type 1 ICP22 represses viral promoter activity and complements the replication of an ICP22 null virus. J Virol (2009) 0.89
Genome sequence of herpes simplex virus 1 strain McKrae. J Virol (2012) 0.88
Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci (2002) 0.88
Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J Pharmacol Exp Ther (2013) 0.87
Fluorogenic Tagging of Peptide and Protein 3-Nitrotyrosine with 4-(Aminomethyl)-benzenesulfonic Acid for Quantitative Analysis of Protein Tyrosine Nitration. Chromatographia (2010) 0.87
Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J Med Chem (2012) 0.86
N-terminal phosphorylation sites of herpes simplex virus 1 ICP0 differentially regulate its activities and enhance viral replication. J Virol (2012) 0.86
Dopamine D(2) receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse. J Neurochem (2010) 0.84
hTERT extends the life of human fibroblasts without compromising type I interferon signaling. PLoS One (2013) 0.84
Decreased activity and enhanced nuclear export of CCAAT-enhancer-binding protein beta during inhibition of adipogenesis by ceramide. Biochem J (2002) 0.83
Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. ACS Chem Biol (2014) 0.83
Herpes simplex virus 1 ICP0 phosphorylation site mutants are attenuated for viral replication and impaired for explant-induced reactivation. J Virol (2011) 0.83
CK2 inhibitors increase the sensitivity of HSV-1 to interferon-β. Antiviral Res (2011) 0.82
HSV-1 strain McKrae is more neuroinvasive than HSV-1 KOS after corneal or vaginal inoculation in mice. Virus Res (2013) 0.82
Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. ASN Neuro (2012) 0.81
HSV-1 ICP22: hijacking host nuclear functions to enhance viral infection. Future Microbiol (2013) 0.80
Nerve growth factor blocks the glucose-induced down-regulation of caveolin-1 expression in Schwann cells via p75 neurotrophin receptor signaling. J Biol Chem (2003) 0.80
Herpes simplex virus 1 ICP22 but not US 1.5 is required for efficient acute replication in mice and VICE domain formation. J Virol (2013) 0.78
p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide. J Mol Neurosci (2007) 0.77
Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy. Acta Neuropathol Commun (2013) 0.75
Heat shock response and insulin-associated neurodegeneration. Trends Pharmacol Sci (2011) 0.75
A flow cytometric assay for the study of E3 ubiquitin ligase activity. Cytometry A (2009) 0.75